Plasma insulin-like growth factor I and IGF binding protein 3 levels in patients with acute cerebral ischemic injury

Stroke

Volumn 28, Issue 9, 1997, Pages 1744-1748

  Schwab, Stefan ^a   Spranger, Matthias ^b   Krempien, Sebastian ^b   Hacke, Werner ^b   Bettendorf, Markus ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NONE

Author keywords

Cerebral ischemia; Growth factors; Neuroprotection; Stroke outcome

Indexed keywords

MESSENGER RNA; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; BRAIN HYPOXIA; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN MATURATION; BRAIN PROTECTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FETUS DEVELOPMENT; HUMAN; MALE; PRIORITY JOURNAL; STROKE;

EID: 0030828440     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.28.9.1744     Document Type: Article

References (45)

1. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16:3-34.
2. Beck KD, Powell-Braxton L, Widmer HR, Valverde J, Hefti F. IGF-1 gene disruption results in reduced brain size, CNS hypomyelination, and loss of hippocampal granule and striatal paralbumin-containing neurons. Neuron. 1995;14:717-730.
3. Zackenfels K, Oppenheim RW, Rohrer H. Evidence for an important role of IGF-1 and IGF-II for the early development of chick sympathetic neurons. Neuron. 1995;14:731-741.
4. Gluckman PD, Klempt N, Guan J, Mallard EC, Sirimanne E, Dragunow M, Klempt M, Singh K, Williams CE, Nikolics K. A role for IGF-1 in the rescue of CNS neurons following hypoxic-ischemic injury. Biochem Biophys Res Commun. 1992;182:593-599.
5. Beilharz EJ, Bassett NS, Sirimanne ES, Williams CE, Gluckman PD. Insulin-like growth factor II is induced during wound repair following hypoxic-ischemic injury in the developing rat brain. Mol Brain Res. 1995;25:81-91.
6. Stephenson DT, Rash K, Clemens JA. Increase in insulin-like growth factor II receptor within ischemic neurons following focal cerebral infarction. J Cereb Blood Flow Metab. 1995;15:1022-1031.
7. Knusel B, Michel PP, Schwaber JS, Hefti FF. Selective and nonselective stimulation of central cholinergic and dopaminergic development in vitro by nerve growth factor, basic fibroblast growth factor, epidermal growth factor insulin and the insulin-like growth factor 1 and 2. J Neurosci. 1990;10:558-570.
8. Mueller RV, Hunt TK, Tokunaga A, Spencer EM. The effect of insulinlike growth factor I on wound healing variables and macrophages in rats. Arch Surg. 1994;129:262-265.
9. Klempt ND, Klempt M, Gunn AJ, Singh K, Gluckman PD. Expression of insulin-like growth factor binding protein-2 following transient hypoxia-ischemia in the infant rat brain. Mol Brain Res. 1992;15:55-61.
10. Bergstedt K, Wieloch T. Changes in insulin-like growth factor 1 receptor density after transient cerebral ischemia in the rat: lack of protection against ischemic brain damage following injection of insulin-like growth factor 1. J Cereb Blood Flow Metab. 1993;13: 895-898.
11. Guan J, Williams CE, Skinner SJM, Mallard ED, Gluckman PD. The effect of insulin-like growth factor (IGF)-1, IGF-2, and des-IGF-1 on neuronal loss after hypoxic-ischemic brain injury in adult rats: evidence for a role for IGF binding proteins. Endocrinology. 1996;137:893-898.
12. Faber J, Kirkegaard C, Rasmussen B, Westh H, Busch-Sorensen M, Jensen IW. Pituitary-thyroid axis in critical illness. J Clin Endocrinol Metab. 1987;65:315-320.
13. Van den Berghe G, De Zegher F, Lauwers P. Dopamine suppresses pituitary function in infants and children. Crit Care Med. 1994;22: 1747-1753.
14. Van den Berghe G, De Zegher F, Lauwers P, Veldhuis JD. Growth hormone secretion in critical illness: effect of dopamine. J Clin Endocrinol Metab. 1994;79:1141-1146.
15. Scandinavian Stroke Study Group. Multicenter trial of hemodilution in ischemic stroke: background and study protocol. Stroke. 1985;16:885-890.
16. Teasdale G, Jannett B. Assessment of outcome after severe brain damage. Lancet. 1975;1:480-484.
17. Rankin J. Cerebral vascular accidents in people over the age of 60: prognosis. Scott Med J. 1957;2:200-215.
18. Blum W. Insulin-like growth factors and their binding proteins. In: Ranke MB, ed. Diagnostics of Endocrine Function in Children and Adolescents. Heidelberg, Germany: Barth Verlag: 1996:190-218.
19. Nieto-Sampedro M, Lewis ER, Cotman CW, Manthorpe M, Skaper SD, Barbin G, Longo FM, Varon S. Brain injury causes a time-dependent increase in neurotrophic activity at the lesion site. Science. 1982;217:860-861.
20. Zhu CZ, Auer RN. Intraventricular administration of insulin and IGF-1 in transient forebrain ischemia. J Cereb Blood Flow Metab. 1994;14:237-242.
21. Guan J, Williams C, Gunning M, Mallard C, Gluckman P. The effect of IGF-1 treatment after hypoxic-ischemic brain injury in adult rats. J Cereb Blood Flow Metab. 1993;13:609-616.
22. Rodriguez-Tarduchy G, Collins MKL, Garcia I, Lopez-Rivas A. Insulin-like growth factor-1 inhibits apoptosis in IL-3-dependent hemopoietic cells. J Immunol. 1992;149:535-540.
23. Neff NT, Prevette D, Houenou LJ, Lewis ME, Glicksman MA, Yin Q, Oppenheim RW. Insulin-like growth factors: putative muscle-derived trophic agents that promote motoneuron survival. J Neurobiol. 1993;24:1578-1588.
24. Reinhardt RR, Bondy CA. Insulin-like growth factors cross the blood-brain barrier. Endocrinology. 1994;135:1753-1761.
25. Guan J, Skinner SJ, Beilharz EJ, Hua KM, Hodgkinson S, Gluckman PD, Williams CE. The movement of IGF-1 into the brain parenchyma after hypoxic-ischemic injury. Neuroreport. 1996; 7:632-636.
26. Byrne TA, Morrisey TB, Gatzen C, Benfell K, Nattakom TV, Scheltinga MR, LeBoff MS, Ziegler TR, Wilmore DW. Anabolic therapy with growth hormone accelerates protein gain in surgical patients requiring nutritional rehabilitation. Ann Surg. 1993;218: 400-418.
27. Jeevanandam M, Holaday NJ, Petersen SR. Plasma level of insulin-like growth factor binding protein-3 in acute trauma patients. Metabolism. 1995;44:1205-1208.
28. Wojnar MM, Fan J, Frost RA, Gelato MC, Lang CH. Alterations of the insulin-like growth factor system in trauma patients. Am J Physiol. 1995;268:970-977.
29. Houston-Bolze MS, Downing MT, Saved AM, Williford JH. Serum insulin-like growth factor binding protein-3 responds differently to trauma in men and women. Crit Care Med. 1996;24:1988-1992.
30. Wilmore DW. Growth hormone and growth factors in catabolic illness. Endocrinol Metab. 1995;2(suppl B):77-84.
31. Hund E. Neuromuscular complications in the ICU: the spectrum of critical illness-related conditions causing muscular weakness and weaning failure. J Neurol Sci. 1996;136:10-16.
32. Kupfer SR, Underwood LE, Baxter RC, Clemmons DR. Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously. J Clin Invest. 1993;91:391-396.
33. Davalos A, Ricart W, Gonzalez-Huix F, Soler S, Marrugat J, Molins A, Suner R, Genis D. Effect of malnutrition after acute stroke on clinical outcome. Stroke. 1996;27:1028-1032.
34. Olsson T, Marklund N, Gustafson Y, Näsman B. Abnormalities at different levels of the hypothalamic-pituitary-adrenocortical axis early after stroke. Stroke. 1992;23:1573-1576.
35. Franceschini R, Gandolfo C, Cataldi A, Del Sette M, Cianciosi P, Finocchi C, Rolandi E, Barreca T. Twenty-four-hour β-endorphin secretory pattern in stroke patients. Stroke. 1994;25:2142-2145.
36. Culebras A, Miller M. Absence of sleep-related elevation of growth hormone level in patients with stroke. Arch Neurol. 1983;40: 283-286.
37. Pepper GM, Koenigsberg R, Zito JL, Deutsch S. Alterations of serum pituitary hormone levels in postmenopausal women with stroke. Stroke. 1993;24:805-808.
38. Sander D, Klingelhöfer J. Changes of circadian blood pressure patterns after hemodynamic and thromboembolic brain infarction. Stroke. 1994;25:1730-1737.
39. Hantai D, Akaaboune M, Lagord C, et al. Beneficial effects of insulin-like growth factor-1 on wobbler mouse motoneuron disease. J Neurol Sci. 1995;129(suppl):122-126.
40. Li L, Oppenheim RW, Lei M, Houenou J. Neurotrophic agents prevent motoneuron death following sciatic nerve section in the neonatal mouse. J Neurobiol. 1994;25:759-766.
41. Lewis ME, Neff NT, Contreras PC, Strong DB, Oppenheim RW, Grebow PE, Vaught JL. Insulin-like growth factor I: potential for treatment of motor neuronal disorders. Exp Neurobiol. 1993;124: 73-88.
42. Festoff BW, Yang SX, Vaught J, Bryan C, Ma JY. The insulin-like growth factor signaling system and ALS neurotrophic factor treatment strategies. J Neurol Sci. 1995;129(suppl):114-121.
43. Johnston BM, Mallard EC, Williams CE, Gluckman PD. Insulin-like growth factor-1 is a potent neuronal rescue agent after hypoxic-ischemic injury in fetal lambs. J Clin Invest. 1996;97: 300-308.
44. Mattson MP, Cheng B. Growth factors protect neurons against excitotoxic/ischemic damage by stabilizing calcium homeostasis. Stroke. 1993;24:1136-140.
45. Zhang Y, Tatsuno T, Carney JM, Mattson MP. Basic FGF, NGF, and IGFs protect hippocampal and cortical neurons against iron-induced degeneration. J Cereb Blood Flow Metab. 1993;13:378-388.